ALT5 Sigma (NASDAQ:AIFC) Issues Quarterly Earnings Results

ALT5 Sigma (NASDAQ:AIFC) released its quarterly earnings results on Monday. The company reported $0.42 earnings per share (EPS) for the quarter, Zacks reports. ALT5 Sigma had a negative net margin of 2,483.94% and a negative return on equity of 68.25%.

ALT5 Sigma Trading Up 3.9%

Shares of AIFC stock traded up $0.02 during trading hours on Monday, hitting $0.42. 1,085,552 shares of the company were exchanged, compared to its average volume of 2,509,992. The company has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.98. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 0.82. ALT5 Sigma has a fifty-two week low of $0.36 and a fifty-two week high of $8.74.

Institutional Investors Weigh In On ALT5 Sigma

Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. acquired a new stake in ALT5 Sigma in the third quarter worth $33,000. Schonfeld Strategic Advisors LLC bought a new position in shares of ALT5 Sigma in the 3rd quarter worth $45,000. Bridgeway Capital Management LLC lifted its holdings in shares of ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock worth $140,000 after purchasing an additional 1,661 shares in the last quarter. Raymond James Financial Inc. grew its position in ALT5 Sigma by 39,884.0% in the 3rd quarter. Raymond James Financial Inc. now owns 19,992 shares of the company’s stock valued at $54,000 after purchasing an additional 19,942 shares during the period. Finally, SIH Partners LLLP bought a new stake in ALT5 Sigma during the 3rd quarter valued at $54,000. 6.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALT5 Sigma in a report on Tuesday, July 14th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.